EFPIA EVENT January 29th 2015 – Going Live: Implementation of the Disclosure Code

How does the pharmaceutical disclosure code affect health care providers? This event is part of EFPIA’s Responsible Transparency initiative, a public information campaign launched to boost pharmaceutical industry preparedness with complying to new disclosure rules for certain financial and other transfers of value with healthcare professionals and organisations. This event will inform the public on the progress of disclosure on a European and member state level. About the event

Read More »

EFPIA in Greece | Transparency Code is a “Great Opportunity” to Put Things in a Different Context

As Greece rebuilds after the financial crisis, adopting the EFPIA code on financial disclosure will be a source of greater confidence, improving the environment for investment and growth, says SFEE President Konstantinos Frouzis. The EFPIA code on transfers of value is “a very important development” that enables the national body in Greece, the Association of Pharmaceutical Companies (SFEE), to play its part in the nation’s recovery. To read the article by Konstantinos Frouzis

Read More »

EFPIA | Making Moves to Avoid Unintended Consequences of Disclosure

Member companies and organisations report good headway on the technical aspects of disclosure. Now it is critical to ensure that publishing transfers of value does not deter healthcare professionals from engaging with the industry, says Richard Bergström, Director General of EFPIA. To read the article by Richard Bergström

Read More »

Interview with Tim McGuire, Director, Global Health Care Professional Reporting, Eli Lilly & Company

The move across Europe to publically disclose the pharmaceutical industry’s financial interactions with Health Care Professionals (HCPs) and Health Care Organizations (HCOs) will inevitably draw more attention to the relationship between companies and healthcare providers. While some may be concerned about the potential negative impact of this type of information, the opposite is true, says McGuire. Disclosure of individual financial relationships between industry and HCPs and HCOs will be a positive force, and further highlight the need and importance of cooperation between industry, academia, clinicians, healthcare organisations and patients’ groups in at least three areas: – the need for collaboration …

Read More »

EFPIA director Richard Bergström | Learning the Lessons From the US on Disclosure

The US Open Payments database got off to a less than happy start. EFPIA will tap into this experience to inform implementation of the code on disclosure in Europe, says Richard Bergström, Director General of EFPIA. There are two big differences between the US and Europe in moves to disclose transfers of value from pharma companies to healthcare professionals. The first is that the US created a legal requirement to disclose under the Sunshine Act, whereas for the most part, disclosure will be voluntary in Europe. The second difference is that of scale, with the Centers for Medicare and Medicaid …

Read More »